Stephanie Howard, PA
Medical · Knoxville, TNNPI 1083903306
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Pfizer at 38.9% of the total. Reporting peaked in 2021 at $5,636 and has fallen 83.4% since, to $934 in 2025. Among medical clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 656 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Sumitomo Pharma America, Inc.$4K
- AbbVie$1K
- Novo Nordisk$955
- Astellas Pharma US Inc$875
- Mayne Pharma Commercial LLC$811
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$8,79048%
- Travel & lodging$3412%
- Food & beverage$8,61747%
- Education$3882%
- Gifts$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $7,084 |
| Sumitomo Pharma America, Inc. | 43 | $3,605 |
| AbbVie | 135 | $1,164 |
| Novo Nordisk | 65 | $955 |
| Astellas Pharma US Inc | 26 | $875 |
| Mayne Pharma Commercial LLC | 39 | $811 |
| Therapeuticsmd, Inc. | 33 | $426 |
| Exeltis, USA Inc. | 21 | $368 |
| Currax Pharmaceuticals LLC | 21 | $319 |
| Myovant Sciences Inc. | 32 | $318 |
| Ascend Therapeutics US, LLC | 94 | $305 |
| Millicent US Inc | 13 | $255 |
| Avion Pharmaceuticals | 18 | $247 |
| Aspira Women's Health Inc | 4 | $235 |
| Biohaven Pharmaceuticals, Inc. | 6 | $187 |
| Lilly USA, LLC | 11 | $180 |
| Exact Sciences | 7 | $121 |
| Mycovia Pharmaceuticals, Inc. | 5 | $115 |
| Alfasigma USA, Inc. | 1 | $101 |
| Evofem Biosciences, Inc. | 4 | $62 |
| Daiichi Sankyo Inc. | 4 | $60 |
| Agile Therapeutics, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Scynexis, Inc. | 3 | $48 |
| Lupin Inc. | 2 | $45 |
| Hologic Sales And Service, LLC | 2 | $29 |
| Bayer | 1 | $26 |
| Shield Therapeutics Inc | 1 | $24 |
| Astellas Pharma Global Development | 1 | $23 |
| Sage Therapeutics, LLC | 1 | $19 |
| Organon | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Dysis Medical, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYFEMBREE$7,191
- BIJUVA$125
- NURTEC ODT$125
- NEXTSTELLIS$124
How this compares
$18,206 in reported general payments places this provider in the 95th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 59 | $20,004 |
| Estradiol | 130 | $6,468 |
| BijuvaEstradiol/Progesterone | 16 | $4,789 |
| ValacyclovirValacyclovir Hcl | 19 | $695 |
| Terconazole | 12 | $397 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 19 | $289 |
| Fluconazole | 19 | $238 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $150 |
| Medroxyprogesterone Acetate | 19 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $7,084 | $20,00459 claims |
| Therapeuticsmd, Inc.Bijuva | $426 | $4,78916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 medical providers in Tennessee.
Other medical in Knoxville
- Janet BreedingKnoxville$15K
- Paul MabenKnoxville$13K
- Tara PiankoKnoxville$8K
- Jaan KellyKnoxville$6K
- Tonya JonesKnoxville$5K
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Evan HatfillNashville$18K
- Meredith McDanielChattanooga$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.